In early 2026, the most lucrative segment of the German off-patent industry is shifting toward "complex generics" and biosimilars as several high-value biologic patents expire across the European Union. These 2026 biosimilar launches are drastically reducing the cost of treatment for oncology and rheumatoid arthritis, allowing statutory health insurers to redirect savings toward other...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
คลิกดาวน์โหลด
Spanish 
thai
English
French
Portuguese
Italiano
Romaian
Portuguese (Brazil)
china